<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465478</url>
  </required_header>
  <id_info>
    <org_study_id>QL060308</org_study_id>
    <nct_id>NCT00465478</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mononuclear Cells Transplantation in Treating Diabetes Patients</brief_title>
  <official_title>Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Patients With Type 1 or 2 Diabetes Mellitus-a Phase 1/2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the safety and efficiency of autologous bone marrow mononuclear cell&#xD;
      transplantation in treating patients with type 1 or 2 Diabetes Mellitus. We hypothesize that&#xD;
      autologous bone marrow stem cell transplantation will promote β-cells regeneration by&#xD;
      directly differentiated from the transplanted BMMCs or stimulated local stem cells&#xD;
      regeneration and thus decrease or eliminate the need of exogenous insulin and improve β-cells&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 1 or 2 Diabetes mellitus will be recruited according to eligibility&#xD;
      criteria. Bone marrow mononuclear cells (BMMCs) will be separated from the bone marrow&#xD;
      aspirate of each patient and be directly delivered to pancreas via splenic artery with the&#xD;
      distal lumen occlusion through an arterial catheter. All patients will be explained in&#xD;
      details about the procedures involved in BMMC transplantation and sign the informed consent&#xD;
      for the study; The Ethics Committee of Qilu hospital, ShanDong university approved the&#xD;
      treatment protocol. All patients undergo scheduled follow-up evaluations for 5 years after&#xD;
      transplantation. Clinical, hematological, metabolical evaluations are performed to analyses&#xD;
      the effect of the transplant, Patients fitting the inclusion criteria but not agreeing to&#xD;
      perform the transplantation are the control group and will received the regular OHA and/or&#xD;
      insulin therapy .They are followed in parallel with transplanted patients and will be&#xD;
      subjected to the same follow-up management including extensive endocrinological monitoring,&#xD;
      diet and exercise program as transplantation patients during the follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exogenous insulin requirement; Hemoglobin A1C; Glucose and C-peptide level;</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment parameter: amylase, hepatic function,renal function,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile, autoantibody， Quality of life</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow mononuclear cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 or type 2 diabetes&#xD;
&#xD;
          -  Between 16 to 65 years of age&#xD;
&#xD;
          -  Requiring daily exogenous insulin injection for the glycaemic control&#xD;
&#xD;
          -  With poor β-cell function&#xD;
&#xD;
          -  Body mass index (BMI) &lt; 28&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute or chronic infections&#xD;
&#xD;
          -  Chronic uncompensated organic insufficiency including heart, liver, renal and lung&#xD;
&#xD;
          -  Any malignancies, congenital or acquired immunodeficiency&#xD;
&#xD;
          -  Hematological diseases or coagulopathy&#xD;
&#xD;
          -  Acute or chronic pancreatitis&#xD;
&#xD;
          -  History of thoracic or abdominal aorta diseases&#xD;
&#xD;
          -  Allergy to iodine&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beihua Kong, MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Chen, MD</last_name>
    <phone>0086-531-82169408</phone>
    <email>chenli3@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xingli Wang, MD PhD</last_name>
    <phone>832-355-9939</phone>
    <email>xlwang@bcm.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Chen, MD</last_name>
      <phone>0086-531-82169408</phone>
      <email>chenli3@medmai.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xingli Wang, MD,PhD</last_name>
      <phone>832-355-9939</phone>
      <email>xlwang@bcm.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Li Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xingli Wang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weikai Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianjun Dong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuanxiao Tang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinguo Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lei Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.qiluhospital.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 24, 2007</study_first_submitted>
  <study_first_submitted_qc>April 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2007</study_first_posted>
  <last_update_submitted>April 24, 2007</last_update_submitted>
  <last_update_submitted_qc>April 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2007</last_update_posted>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Bone Marros Mononuclear Cells</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

